|
|
News Breaks | | | | September 18, 2012 | | 08:05 EDT |  | NAVB | Navidea begins enrollment for Phase 2 study of NAV4694
Navidea Biopharmaceuticals announced that enrollment has commenced at two sites participating in its Phase 2, open-label, safety and efficacy PET imaging study of NAV4694 for detection of cerebral b-amyloid plaque in subjects diagnosed with probable Alzheimer's disease. The study is designed to compare images from subjects with probable AD with similarly aged and young healthy volunteers. Two trial sites are currently enrolling subjects: Molecular NeuroImaging, LLC in New Haven, CT, which dosed the first patient in the study; and the Alzheimer's Disease Center at Quincy Medical Center in Quincy, MA. | |
|
News For NAVB From The Last 14 Days Check below for free stories on NAVB the last two weeks. |
|
|
| May 15, 2013 | | 16:37 EDT | | NAVB | Nordion signs contract manufacturing agreement with Navidea
 Subscribe for More Information | |
|
|
|
|
|
|
